Drawing for TATAA

USPTO serial 77018897

TATAA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
SOBRAL, CHRISTINA
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with TATAA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Carl Oppedahl

Oppedahl Patent Law Firm LLCP O Box 5940Dillon, CO 80435-5940UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic apparatus for medical use, namely, human endogenous control panel kits, comprising primers for candidate endogenous control genes, control DNA, PCR reagents, and computer softwareABANDONED—
041Organization of seminars, working groups, research groups and educational conventions, in the field of biomedicine; training for handling scientific instruments and apparatus for research in laboratoriesABANDONED—
042Testing of pharmaceuticals, medical research, design of medical research projects for others, analysis in the field of biomedicine, namely, analysis of test and research results; biological, clinical and medical research; research and consultancy related to research in genetics and biochemistry; research and development related to surgical and medical apparatus and instruments; scientific research in the field of genetics and biomedicine; pharmaceutical research and development servicesABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 19, 2010MAB4ABANDONMENT NOTICE MAILED - INTER PARTES DECISION—
May 19, 2010ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
May 19, 2010OP.TOPPOSITION TERMINATED NO. 999999—
May 19, 2010OP.SOPPOSITION SUSTAINED NO. 999999—
May 11, 2010ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 11, 2010REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 24, 2008OP.IOPPOSITION INSTITUTED NO. 999999—
Jul 24, 2008OPPFOPPOSITION PAPERS RECEIVED AT TTAB—
Jun 24, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 4, 2008NPUBNOTICE OF PUBLICATION—
May 20, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 16, 2008ALIEASSIGNED TO LIE—
May 15, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 15, 2008XAECEXAMINER'S AMENDMENT ENTERED—
May 15, 2008GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 15, 2008GNEAEXAMINERS AMENDMENT E-MAILED—
May 15, 2008CNEAEXAMINERS AMENDMENT -WRITTEN—
May 14, 2008ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Mar 24, 2008PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Mar 7, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 7, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 1, 2008RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Mar 1, 2008ALIEASSIGNED TO LIE—
Feb 28, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 27, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 27, 2008ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Aug 31, 2007GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Aug 31, 2007GNSLLETTER OF SUSPENSION E-MAILED—
Aug 31, 2007CNSLSUSPENSION LETTER WRITTEN—
Aug 30, 2007XAECEXAMINER'S AMENDMENT ENTERED—
Aug 30, 2007GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 30, 2007GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 30, 2007CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 28, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 28, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 28, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 28, 2007GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 28, 2007CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 27, 2007DOCKASSIGNED TO EXAMINER—
Oct 16, 2006NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance